The Ebola virus causes a severe hemorrhagic fever for which no approved vaccines or treatments are yet available. Two viral glycoproteins play an important role in Ebola viral pathogenesis. These two proteins, sGP and GP, share an identical 295 amino acid sequence at their N termini, but have different C termini that lead to different patterns of disulfide bonding and different tertiary structures. Importantly, the different structures lead to unique roles in pathogenesis for the two proteins. GP exists as a trimer on the viral surface and mediates cell attachment and fusion. In contrast, sGP is a dimer and is secreted abundantly from infected cells. In natural infection, the majority of antibodies are bound by the secreted sGP and not the virion surface GP. Understanding how to elicit antibodies specific for GP will be critical for the design of vaccines and immunotherapeutics for long-term and immediate immunity in case of natural outbreak or deliberate release of Ebola virus. X-ray crystallography is the best way to clearly map structural differences between sGP and GP. These structures will also provide the templates by which we may understand the roles of these proteins in the viral life cycle.
Our specific aims are to determine X-ray crystal structures of sGP and GP and to characterize antibodies directed against them. Our objectives are to (1) determine why it is difficult to elicit neutralizing antibodies against GP in natural infection, (2) identify structural elements unique to GP that can be exploited for design of vaccines and immunotherapeutics, (3) map ligand and receptor binding sites on the glycoproteins and importantly, (4) map key differences in GP sequence from Ebola viral subtypes that are pathogenic and nonpathogenic to humans. Our extensive preliminary data demonstrate the feasibility of these specific aims.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Virology - A Study Section (VIRA)
Program Officer
Repik, Patricia M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Holtsberg, Frederick W; Shulenin, Sergey; Vu, Hong et al. (2016) Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol 90:266-78
Pallesen, Jesper; Murin, Charles D; de Val, Natalia et al. (2016) Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 1:16128
Bornholdt, Zachary A; Turner, Hannah L; Murin, Charles D et al. (2016) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351:1078-83
Goba, Augustine; Khan, S Humarr; Fonnie, Mbalu et al. (2016) An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis 214:S110-S121
Robinson, James E; Hastie, Kathryn M; Cross, Robert W et al. (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7:11544
Flyak, Andrew I; Shen, Xiaoli; Murin, Charles D et al. (2016) Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell 164:392-405
Boisen, Matt L; Oottamasathien, Darin; Jones, Abigail B et al. (2015) Development of Prototype Filovirus Recombinant Antigen Immunoassays. J Infect Dis 212 Suppl 2:S359-67
Murin, Charles D; Fusco, Marnie L; Bornholdt, Zachary A et al. (2014) Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111:17182-7
Saphire, Erica Ollmann (2013) An update on the use of antibodies against the filoviruses. Immunotherapy 5:1221-33
Olal, Daniel; Kuehne, Ana I; Bale, Shridhar et al. (2012) Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol 86:2809-16

Showing the most recent 10 out of 20 publications